NCT02270372 - Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions

Advanced Breast CarcinomaAdvanced Ovarian Carcinoma

Interventions

BIOLOGICAL

ONT-10, Varlilumab combination

"ONT-10 a liposomal synthetic glycopolypeptide MUC1 targeted antigen formulated with PET Lipid A adjuvant.~Varlilumab is a recombinant, fully human mAb of the IgG1κ isotype that specifically binds human CD27."

Trial Locations (4)

10016

NYU Perlmutter Cancer Center, New York

35294

UAB Comprehensive Cancer Center, Birmingham

37203

Sarah Cannon Research Institute, Nashville

80045

University of Colorado, Aurora